Revvity Inc (RVTY) Stock Forecast & Price Target

Revvity is well positioned for a positive long-term outlook because its transformed portfolio combines ~80% recurring revenue, a life sciences franchise tied to recovering pre-clinical spending, and a diagnostics base that is proving resilient ex-China. Management has repeatedly raised FY26 organic growth guidance from 2-3% to 4-5%, while 2Q showed 11% organic growth in Diagnostics and double-digit growth in High-Content Screening, with antibody/reagent mix and +40% incremental margins offering margin upside. The case is further strengthened by AI-enabled discovery and the Signals platform, which serves 47 of the top 50 global pharma and biotech companies and could unlock higher-growth, higher-margin demand through new products and workflow software.

Revvity is facing a weaker fundamental growth profile than its long-range plan implies, as the two largest and highest-growth businesses, Immunodiagnostics and Life Sciences Solutions, representing about 70% of revenue, have not shown clear evidence of a step-up to the 6% to 8% sales growth corridor. Euroimmun and BioLegend have lost momentum, reproductive health is benefiting from the GEL contract but faces tougher comps and declining birth rates, and competitive pressure is rising across reagents, diagnostics, and AI-driven research software. With Immunodiagnostics ex-China running at only mid-to-high single-digit growth versus a 9% to 11% target and Life Sciences only now returning to low-single-digit growth after contracting in 2024 and 2025, the company appears likely to struggle to justify an acceleration thesis.